Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Hematologic Neoplasms × pembrolizumab × Clear all

Phase

Phase 2 2 Phase 1 2 Phase 3 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 84 Carcinoma, Non-Small-Cell Lung 75 Lung Neoplasms 20 Melanoma 17 Squamous Cell Carcinoma of Head and Neck 16 Triple Negative Breast Neoplasms 11 Stomach Neoplasms 10 Head and Neck Neoplasms 10 Carcinoma, Renal Cell 10 Breast Neoplasms 10 Carcinoma 9 Neoplasms 8 Neoplasm Metastasis 8 Endometrial Neoplasms 7 Urinary Bladder Neoplasms 6 Carcinoma, Hepatocellular 6 Colorectal Neoplasms 5 Carcinoma, Transitional Cell 5 Uterine Cervical Neoplasms 4 Prostatic Neoplasms 4 Esophageal Neoplasms 4 Cholangiocarcinoma 4 Thoracic Neoplasms 3 Skin Neoplasms 3 Respiratory Tract Neoplasms 3 Respiratory Tract Diseases 3 Ovarian Neoplasms 3 Neoplasms by Site 3 Lung Diseases 3 Gallbladder Neoplasms 3

Interventions

Olanzapine 4 Cyclophosphamide 4 Voriconazole 3 Tranexamic Acid 3 Standard of Care 3 letermovir 2 fludarabine phosphate 2 Zoledronic Acid 2 Whole-Body Irradiation 2 Practice Guidelines as Topic 2 Peripheral Blood Stem Cell Transplantation 2 Mycophenolic Acid 2 Methods 2 Educational Status 2 Early Intervention, Educational 2 Doxorubicin 2 Cyclosporins 2 Cyclosporine 2 trihexyltetradecylphosphonium chloride 1 thymoglobulin 1 shengxuening 1 posaconazole 1 pembrolizumab 1 olaparib 1 nilotinib 1 lenvatinib 1 ferrous succinate 1 fedratinib 1 cilgavimab and tixagevimab drug combination 1 apixaban 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03486873 2026-03-16

MK-3475-587

Merck Sharp & Dohme LLC

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡